The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.

Inclusion Criteria:

• Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies

Exclusion Criteria:

• ALT/AST>3 times the ULN or have hepatic disease
• have severe visual field loss, cranial nerve palsies or intracranial HTN that requires surgery to decompress the tumor
• unwilling to self-administer the medication.